New heart pump aims to make risky artery procedures safer

NCT ID NCT04477603

Ongoing Disease control Sponsor: Abiomed Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a temporary heart pump called Impella ECP in 100 adults undergoing high-risk angioplasty. The pump helps maintain blood flow during the procedure. Researchers are checking if the device is safe and works as intended, with follow-up for 30 days after the procedure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Impella ECP (a temporary heart pump device)
What this could lead to: If successful, this device could provide safer hemodynamic support during high-risk angioplasty, potentially reducing complications.
What could go wrong: This is an early feasibility study with only 100 participants, so results may not apply broadly. The device carries risks like bleeding or vessel damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH RISK PERCUTANEOUS CORONARY INTERVENTION

Contacts and locations

Locations

Henry Ford Health St. John Hospital

Detroit, Michigan, 48236, United States
Henry Ford Hospital

Detroit, Michigan, 48202, United States
The Christ Hospital

Cincinnati, Ohio, 45219, United States
The Valley Hospital

Paramus, New Jersey, 07652, United States
Tufts Medical Center

Boston, Massachusetts, 02111, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.